Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies

Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies

Abstract Background Isocitrate dehydrogenase (IDH) is an appealing target for anticancer therapy, and IDH (IDH1/2) inhibitors have been approved for targeted therapy of acute myeloid leukemia (AML) and Cholangiocarcinoma. The therapeutic potential of IDH inhibitors for non‐small‐cell lung cancer (NS...

Full description

Bibliographic Details
Main Authors: Shuchen Chen, Honglin Zhu, Meizi Jin, Hongling Yuan, Zhenzhen Liu, Jielin Li, Xiang Zhang, Lihui Meng, Ting Li, Yuzhu Diao, Hong Gao, Chengyu Hong, Xinjiang Zhu, Jian Zheng, Fei Li, Yanling Niu, Tonghui Ma, Xiaoling Li
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:Cancer Medicine
Subjects:
IDH inhibitor
IDH1
IDH2
next‐generation sequencing
non‐small‐cell lung cancer
Online Access:https://doi.org/10.1002/cam4.4764

Internet

https://doi.org/10.1002/cam4.4764

Similar Items